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Interpretation of structural imaging in normal persons depends
critically on beliefs concerning the individuals being imaged. Clarity in
key general terms is needed before proceeding with a review of this
topic, particularly because the same term may be used in both a
theoretical and a practical sense in the literature without distinction.
Cognitive normality, for example, may denote concepts of a particular
range of expected behaviors attributed to brain performance together
with theoretical factors contributing to variability in this performance.
In practice cognitive normality may be assessed using interviews that
probe relevant behaviors based on clinical knowledge and experience,
or deﬁned by scores on cognitive tests [1–3].
Themutual interaction between the theoretical and practical sense
of cognitive normality (CN) in persons being imaged is revealed in its
application to aging [4]. Is CN the ideal preservation of adult brain
performance at any time point, in which case psychometric test norms
might be independent of age, or should CN include acknowledgement
of universally observed declines with age, particularly in certain
domains such as processing speed, and hence interviews and
cognitive tests should somehow adjust for age [5]?
A second general term relevant to the interpretation of structural
imaging in cognitively normal persons at risk of AD is atrophy.Atrophy as a medical concept refers to the reduction of brain
substance relative to a presumed prior healthy normal state, and in
addition implies that this reduction is an effect of disease rather than
from a normal process, e.g., pruning due to developmental changes
during puberty. Some studies are designed to assess longitudinal
change and thus deﬁne an atrophy rate, but cross-sectional studies
have to make an assumption of comparability with the normal control
group when referring to atrophy [6].
A second issue related to atrophy is uncertainty in the apportion-
ment of structural (e.g., volume, thickness or shape) differences
between: (1) longstanding effects of brain development or prior
injury, (2) ongoing alterations due to aging or to disease processes
that are not primary to the study, and (3) the focus of the study, in the
current instance risk of clinical AD. By clinical AD is meant the
expression of the underlying pathophysiology of AD in the form of
memory or other symptoms. Developmental endowments, life
experiences or speciﬁc activities such as exercise could both protect
the individual from clinical AD and subtly inﬂuence brain structures,
e.g., by increasing cortical thickness, thus decreasing risk of AD even
though they have no direct connection to AD pathophysiology [7]. The
essence of the problem is whether one is “ﬁnding the beginning or
predicting the future” [8]. However, the issue of apportionment is
often not explicitly considered in the literature.
Finally, the general term “risk of AD” needs to be qualiﬁed by being
speciﬁc about the time interval over which risk is deﬁned. It is
important to recognize the observation period of individual imaging
studies because if they are short, there is little time for the underlying
biology of AD to express itself, whereas if it is long, there is greater
likelihood of cognitive decline or AD expression but also greater
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disease. Likewise with the term “prediction”, but that term is avoided
herein.
This review will attempt to be mindful of the general terms CN,
atrophy and AD risk as described above, while addressing the
following questions: (1) Are there structural imaging alterations in
CN that precede MCI and AD?, (2) Is there a regional pattern of such
alterations and does this pattern provide insight into AD pathophys-
iology?, and (3) How long before symptoms of AD appear do
structural alterations occur? A context for addressing these questions
is provided ﬁrst in terms of a simple model and a brief description of
brain structural alterations in aging.
2. Conceptual model for AD pathology and expression
A basic framework for this article is illustrated in Fig. 1. In this
simple model, the basic assumptions are that: (1) underlying AD
neuropathology accumulates in many CN persons years before any
cognitive symptoms or even measurable declines in cognitive testing
occur, (2) the brain has intrinsic neural mechanisms that compensate
for injury due to AD neuropathology (ADN) at all stages, e.g. by
synaptic remodeling, and (3) the human brain has inborn, develop-
mental and learned sources of cerebral reserve that may offset theFig. 1. Simple model of the AD timecourse (modiﬁed from [17]). a. Illustration of a statistical
the expected remaining population at each 5-year interval to age 85 based on the US census
persons with AD (black) or MCI (white), or who remain normal (gray), based on US popu
accelerate after age 55. b. Percentage of Braak stages over the same age range based on Br
modality and age in a nominal cohort of persons who develop symptoms of AD at age 75 y
appearance in individuals of the ﬁrst detectable image changes within each modality, some o
appearance of alterations near the time symptoms appear (within a few years). The charac
activation, a subtlety not captured in this simpliﬁed diagram. d. In the nominal cohort, mem
longitudinal assessment, later associated with a complaint noticed by a patient and outside o
range may be dissected out using imaging and other biomarkers of AD neuropathology. Thcognitive effects of injury, or, inversely, speciﬁc liabilities to the effects
of ADN.
To clarify the framework, more needs to be said about “underlying
AD pathology”. Here the essence of AD pathology is taken to be the
coupling between amyloid and tau. In this view beta-amyloid is not
necessarily in the form of an accumulation (as in plaques) particularly
in the earliest stages [9], but it must be present and coupled to
abnormal tau for there to be AD pathology. This coupling could be
mediated through, for example, prion protein [10,11]. Accumulations
of both amyloid and tau are the evidence this coupling has occurred,
and indicate the severity of the process and likely the duration.
Atrophy is taken as evidence of synaptic and neuronal loss or
shrinkage. These changes are accompanied by widespread tau
aggregates within the affected region. The amount of amyloid in a
region does not always correspond with atrophy—in this framework
that is determined by the strength of the coupling with tau (the
signature of an underlying process of synaptic and neuronal
degeneration).
Neuropathologically amyloid alone is not sufﬁcient. Most
radionuclide-label imaging only assesses amyloid, so the coupling
to tau is only a presumption. There is a strong correlation between
tau measured in CSF and (decreased) CSF amyloid and (increased)
brain amyloid. So while not perfect, the amyloid-tau relationship iscohort of 100,000 persons beginning at the age of 25 years, with bar height representing
[88,89]. Each bar divided into proportionate parts representing the expected number of
lation model estimates [89,90]. The incidence of MCI and AD, and overall death rate
aak [89,91,92]. c. Conceptual diagram of the appearance of different image features by
ears, based on results in the current literature [17]. Dotted lines represent the variable
f which may precede symptoms by several years. Solid lines represent the more certain
ter and distribution of image alterations may change over time, e.g., in functional MRI
ory decline within the normal range of scores becomes detectable by sensitive tests and
bservers, but without functional decline. Differences in rate of decline within the normal
ese differences could result in a re-deﬁnition of CN.
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(2-(1-{6-[(2-[F-18]ﬂuoroethyl)(methyl)amino]-2-naphthyl}ethyli-
dene)malononitrile ([(18)F]FDDNP)) may in the future prove better
markers of AD pathology than amyloid-only agents [12]. Tau alone
may be present in other conditions, but it is the coupling with beta-
amyloid that is distinctive of AD pathology. Whether a decoupling
might occur later in the process wherein further neurodegeneration
becomes autocatalyzing is unknown.
Within this framework the mere presence of AD-like brain pathology
by itself doesn't provide enough information to predict later dementia. It
could be that the rate of accumulation is low, at least low enough to be
successfully compensated, or that factors leading to an acceleration of the
ADneuropathologic process are absent. Additional evidence that detected
AD pathology is causing brain dysfunction may be needed in early cases,
e.g., subtle cognitive impairment or at least decline, or brain network
disruption detected by functional studies. However, it is reasonable to
assume that themore pathology that is present, the more likely it is to be
predictive of later AD, and that the absence of pathology is prognostically
favorable [13].
Alzheimer's disease occurs in late life and thus in an environment
of multiple competing causes of death (Fig. 1a). The earliest
Alzheimer's disease neuropathology (Fig. 1b; nominal age range 55–
65 years) occurs in middle adulthood, accompanied by “compensa-
tory” imaging functional changes (Fig. 1c) but unaccompanied by
brain volume loss on imaging or by diminished cognitive performance
(Fig. 1d; [14]). As age and ADN increase (nominal age range 65–
75 years), compensatory functional changes accompany early region-
al brain atrophy associated with increasing global amyloid and
regional tau accumulation. This stage represents the borderland
between CN and early cognitive changes (memory decline±MCI).
Subsequent symptoms of cognitive impairment represent a critical
point beyond which functional alterations, brain atrophy, and
cognitive performance continually worsen (nominal age in this
diagram 75 years). Functional losses in addition to compensations,
increasing atrophy, and diminishing cognitive performance ensue in
diagnosed clinical AD [15–17].
3. Structural imaging in aging
Well-characterized, longitudinally followed cognitively normal per-
sons undergo brain volume losses with age, emphasizing the need for
carefully selected age-matched controls in cross-sectional structural
studies [18–20]. Only longitudinal studies can conﬁrm baseline normal
individualswhodevelop cognitive decline,MCI or ADat some future time.
Retrospectively removing from analysis baseline structural scans fromCN
subjects who later develop MCI or AD could reduce effects of subtle
disease-related volume losses, on the assumption these scans could skew
regional volume distributions for CN [21]. Even when this step is taken,
age-associated volume reductions are still observed. Gray matter volume
reductions with age are generalized, without the relatively selective
regional medial temporal, lateral temporal and parietal reductions
characteristic of AD. Selective volume reduction with age also occurs in
the deep frontal whitematter and genu of the corpus callosum [21,22]. In
one recent study cortical thickness was reduced predominantly in
primary sensorimotor regions, but did not correlate with cognitive
performance, whereas white matter integrity (assessed by fractional
anisotropy) was reduced in genu of corpus callosum and in frontal white
matter, and correlated with deﬁcits of “cognitive control” in 38 CN elders
[23].
Gray matter volume is not a static property and is potentially
modiﬁable in aging. Erickson et al. found that vigorous levels of
baseline physical activity (operationalized as blocks walked per
week) were associated with increased cortical volume, particularly
in premotor and prefrontal regions, 9 years later [24]. Gray matter
volume increases are seen in aging even after short exercise
interventions [25]. The main caveat to these studies is the possibilitythat disease associated with brain volume losses biases toward non-
participation in exercise.
Studies of hippocampal function (using cerebral blood pool
volumemeasurements, CBV) suggest that losses with aging, including
memory decline, may occur in the subiculum and dentate nucleus,
whereas entorhinal functional changes are more speciﬁcally associ-
ated with disease [26], particularly AD. Diabetes may be associated
speciﬁcally with dentate gyrus functional decreases, hippocampal
ischemia with CA1 decreases, and more generalized ischemia both
with CA1 and subiculum sector decreases [27]. A structural study of
hippocampal formation subﬁelds in subjects carefully screened for
vascular risk and diabetes demonstrated an age-related reduction in
subiculum volume commensurate with global gray matter reductions,
but relative preservation of other hippocampal segments (CA1 and
dentate subﬁelds; [28]). These results are consistent with the pattern
of subﬁeld changes associated with speciﬁc pathologies and with
aging seen in CBV-based studies.
Involutional age-related erosion of brain reserve and mild
cognitive decline appears to be a fact of life in brain aging [16].
However, more sensitive methods for evaluating gray and white
matter structure, and ﬁner resolution of these methods to the level of
individual gray matter nuclei and subﬁelds, are now demonstrating
subtle structural alterations that can be apportioned to speciﬁc co-
morbid pathologies. As discussed further on, risk factors for
pathologies, e.g., maternal family history of AD, may be associated
with alterations in gray matter in CN aged subjects. Thus, apportion-
ment of structural alterations between aging involution and under-
lying pathologies may soon be placed on a better scientiﬁc footing.
Finally, effects of intervention such as exercise show that the aging
brain may demonstrate plastic re-growth detectable as structural
change.
4. Structural imaging in MCI
MCI is deﬁned as a mild but deﬁnite decline from previous
cognitive ability, conﬁrmed by a reliable observer, and substantiated
by deﬁcits on neurocognitive testing [29–31]. Generally structural
MRI studies have demonstrated decreased size of the hippocampal
formation in MCI, by rating techniques [32] and in both region-of-
interest [32–36] and voxel-based volumetric studies [32,37–41].
Studies are mixed regarding the presence of more global gray matter
reductions in MCI compared to CN, e.g., in frontal and parietal regions
[32,42,43]. Older adults who have memory complaints but do not
meet formal criteria for MCI may nonetheless show similar gray
matter reductions [32,44].
A recent study based on subjects from the landmark Alzheimer's
disease Neuroimaging Initiative (ADNI) demonstrated that structural
imaging data added signiﬁcantly to the prediction of AD in patients
with amnestic MCI [45]. The study used a modiﬁed version of
freesurfer software [46] to compute cortical thickness and volumes
from salient regions in subjects comparing CN and AD at baseline and
over time using discriminant analysis. The discriminant functions
were then used to compute risk scores for the MCI subjects. Subjects
with high percentile scores were much more likely to convert to AD
(odds ratios of 7.2 for highest vs. lowest percentiles for baseline scans,
increasing to 12.0 when one-year longitudinal change was included in
the analysis).
5. Structural imaging in CN persons at risk of AD
5.1. Overview
This section refers to imaging studies characterizing the brain in
cognitively normal (also denoted by CN in context) subjectswith the goal
of characterizing risk for MCI or AD (cf. Fig. 1). Studies have
operationalized CN by using expected cognitive test scores as they must,
Fig. 2. Voxelwise negative correlation between amyloid burden in normal subjects with
elevated global 11C-PIB binding and hippocampal volume (r=−0.6, p=0.02 using
inferior temporal region). This relationship was not seen in subjects with MCI or AD, or
in other brain regions outside of the inferomedial temporal lobe and parieto-occipital
junction. Views: a—sagittal; b—coronal; c—axial.
With permission from [51].
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question of whether the subjects “truly” have CN from an evolving
theoretical pointof viewbasedon theneurobiologyofAD, because there is
always a better cognitive test, clinical interview, or longitudinal follow-up
method for assessment of cognitive decline that might yet detect a subtle
difference. This is a practical problem only if this potential difference
would alter treatment or prevention, an important unresolved issue.
Despite uncertainty, if risk stratiﬁcation in deﬁned CN subjects could be
accomplished with reasonable accuracy using structural imaging, then
interventions might be made to slow the progress of ADN or to enhance
intrinsic brain compensatory mechanisms before symptoms, perhaps
entirely preventing or at least delaying these symptoms [47,48]. This
considerationmotivates the search for structural, andother, biomarkers of
AD in CN persons.
5.2. Brain structure and amyloid
The issue of deﬁning CN mentioned in the Introduction has a
speciﬁc application to presumed pre-state Alzheimer's disease (AD),
because it has been found that brain amyloid accumulation is
correlated negatively with memory scores in CN, although the scores
are in the normal range [49]. Nonetheless, cognitive differences in
general were not found between the 20–30% of CN with positive
amyloid scans and the remainderwith amyloid negative scans [13,50].
In a group of 95 CN subjects, 32 were found to have elevated 11C-PIB
amyloid brain labeling (PIB-positive; 34%). Again there were no
cognitive differences or mean hippocampal volume differences
between PIB-positive and PIB-negative CN, but there was a negative
correlation between hippocampal volume and inferior temporal PIB
retention in the former group [51]. Other recent studies have
demonstrated decreased volume [52] or cortical thickness [53] in
regions associated with early AD pathology (hippocampus, temporal
neocortex, anterior and posterior cingulate) in CN subjects with
increased amyloid burden. It was structural loss and not amyloid
burden that correlated with cognitive performance in these studies, a
ﬁnding that can be interpreted within our framework as the result of
amyloid coupling to synaptic and neuronal degeneration associated
with abnormal tau.
These ﬁndings suggest that in its early stages amyloid accumu-
lation may not be associated with cognitive alterations but rather
with subtle asymptomatic structural volume loss, implying ongoing
brain injury that is somehow compensated. Evidence that structural
alterations are associated with cognitive performance in CN subjects
with increased amyloid burden, and amyloid burden with subse-
quent cognitive decline, suggests that this state of compensation is
not long-lived [52]. The reverse conclusion, that amyloid accumu-
lation is the consequence of volume loss, is less likely because there
was no correlation of between brain volumes and amyloid burden in
the frontal lobes, for example [51]. Nonetheless, amyloid accumu-
lation correlating with hippocampal volume was located exclusively
in local inferior temporal regions immediately upstream of the
entorhinal cortex and hippocampus, not in other neocortical regions
(Fig. 2).
Amyloid positive subjects are CN in one practical sense but not
necessarily in a theoretical sense, because there is evidence of an
underlying disease process, a process excluded from the concept of
aging, whichmight cause the observed disease biomarker correlations
with memory scores or with brain volumes. In this gray area lies the
borderland between very early mild cognitive impairment (MCI) and
CN aging.
5.3. Longitudinal structural studies
Annual rates of ventricular expansion have shown an increase in
baseline CN subjects who received a clinical diagnosis of MCI within
an average of 2.3 years, with an apparent acceleration of ventricularvolume expansion rate in the two-year lead-up to MCI diagnosis
[51,54]. In a second study with 3.4 years follow-up from the last
structural scan, ventricular expansion rate was associated with
subsequent MCI diagnosis [55]. Volume loss rate in whole brain,
hippocampus and entorhinal cortex was not associated with MCI
conversion in this study, but regional medial temporal boundary shift
atrophy rate has been associated with this conversion in over 6 years
of observation [56].
Because the earliest ADN involves the entorhinal cortex, amygdala,
hippocampus and other medial temporal structures, early atrophy in
these regions could predict normal subjects who will later develop
MCI or AD [57–61]. Medial temporal (particularly entorhinal) baseline
volume also predicted decline on tests of delayed memory in CN
subjects imaged at baseline and followed for 3.8 years [61,62].
An unexpected and signiﬁcant early ﬁnding in the ADNI study was
that temporal lobe atrophy predicted subsequent cognitive decline
even in baseline cognitively normal participants in that study [41,61].
It has since been found that rate of atrophy in medial temporal
structures in these subjects was associated with cognitive decline
assessed by logical memory and AVLT tests [61,63]. These studies have
been supplemented by analyses demonstrating that cortical thinning
can be detected over 1 year in normal subjects, particularly in
temporal and prefrontal regions [64]. These reductions were not
conﬁned to subjects with low CSF beta-amyloid levels, a marker of
potential AD neuropathology, but in subjects with levels below a
threshold, a correlation with cortical thinning was evident [65].
A longitudinal general community study of 511 nondemented
subjects demonstrated that reduced global, hippocampal and amyg-
dalar volumes at baseline were predictive of dementia within an
average of 6 years [66], with the rate of volume change serving as an
independent predictor [66,67]. Another recent study on 136 longitu-
dinally-followed normal subjects undergoing a baseline structural
scan demonstrated that volume in a combined region identiﬁed from
these scans using VBM (anteromedial temporal and left angular gyrus
gray matter; Fig. 3a) predicted MCI within 5 years with 76% accuracy.
Predictive accuracy increased to 87% by combining volume in the
combined region with a cognitive measure, raw Wechsler Memory
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manual medial temporal tracing further supported these results [70].
A second potential structural signature of AD was found in a
collection of cortical thickness measures in two independent groups
of CN subjects using a retrospective comparison between subjects
who developed AD versus groups of 25 control subjects who remained
normal over the same observation periods of 7.1 (7 converters) and
11.1 (8 converters) years [71]. The sample sizes are relatively small
and thus ﬁndings are prudently viewed as preliminary. The regions for
cortical thickness comparison were established from previous studies
of AD. Although medial temporal lobe (MTL), temporal pole, and
superior frontal gyrus thickness was signiﬁcantly less in CN to AD
converters, averaging MTL with six additional region thickness values
appeared to add further predictive power. The additional regions
were inferior temporal, angular gyrus, supramarginal gyrus, superior
parietal, precuneus, and middle frontal gyrus regions segmented inFig. 3. Brain structural alterations in cognitively normal persons at risk of MCI or AD. a.
Volume within a template identiﬁed by retrospective classiﬁcation of baseline scans in
CN subjects demonstrating a region of signiﬁcantly reduced gray matter volume at
baseline in those who later developed MCI within 5 years (yellow-white color scale).
Views: a and d—sagittal; b—coronal; c—axial. Prediction accuracy of volume within this
brain region alone was 76%, and 87% when combined with psychometric data (with
permission from [21]). b. Decreasing rates of conversion from CN to AD over the
observation period by average baseline cortical thickness, averaged across nine regions
of interest, classiﬁed as low (1 SD below the entire cohort mean), average (within 1 SD
of the mean), and high (1 SD above the mean—the rate was zero in this group). Regions
of interest were selected by ﬁnding signiﬁcant differences in cortical thickness between
AD and CN in a prior study (inset left, nine color-coded regions projected on partially
inﬂated brain surface image). Retrospective classiﬁcation of baseline scans in CN
subjects allowed calculation of thickness differences between baseline CN who
developed AD vs. those who remained CN.
With permission from [71].freesurfer. High cortical thickness in some of these regions could have
been protective for conversion to AD, because the conversion rate in
18% of subjects with this signature was zero (Fig. 3b).
5.4. Structural studies in CN involving genetics
Normal subjects with a maternal history of AD (+FHm) have
demonstrated decreased cortical volumes compared to subjects with
a paternal AD history or no family AD history, mainly in frontal regions
[72,73]. Gray matter loss over 2 years in +FHm, however, displayed a
somewhat different pattern, incorporating the dorsal frontal lobes but
also the precuneus and inferotemporal cortex. A maternal inheritance
inﬂuence on both earlier cortical development and later degenerative
change is one explanation for these ﬁndings.
Apolipoprotein E (APOE) is a cholesterol carrier linked with
cardiovascular disease and late-onset AD [74], particularly through
the inﬂuence of the epsilon-4 allele on age of AD onset. Cognitive
decline in CN APOE epsilon-4 carriers diverges from that of non-
carriers before age 60 years according to one model based on
longitudinal observation of approximately 5 years [75]. APOE allele
status was not found to add to risk of future cognitive impairment in
CN subjects over an observation period of 6 years when medial
temporal volume, walking speed and logical memory II baseline
scores were included in the analysis [76]. Increased amyloid burden
has been associated in a dose-dependent manner with the epsilon-4
allele [77] in CN subjects. Reduced gray matter density in the right
medial temporal lobe and in the frontotemporal cortex has been
reported in CN carriers of a single epsilon-4 allele [78]. These ﬁndings
suggest that APOE risk in CN subjects has proxies through amyloid
accumulation and tissue loss in gray matter areas known to harbor
neuropathology early in AD.
Familial Alzheimer's disease (FAD) involving single autosomal
dominant gene mutations with early-onset dementia has been
studied to provide insights into the far more common sporadic,
polygenetic disease late-onset Alzheimer's disease (LOAD). Mutations
in the amyloid precursor protein (APP) gene on chromosome 21 are
quite rare. One study of presymptomatic APP V717Gmutation carriers
demonstrated slight baseline left hippocampal volume difference
compared to controls with a rapid hippocampal volume loss (4.8% per
year, n=3) as symptoms appeared over 2 years [79]. These subjects
retrospectively had lower than expected global or memory scores
despite normal day-to-day function and absence of reported memory
decline. For comparison in a later study in the same family using a
global brain volume technique, median global annualized volume
change was 0.2%/year in 26 matched controls, 0.1%/year in 23 at-risk
carriers who remained well, and 1.5%/per year in 5 who became
symptomatic within 2 years of baseline scan [80]. These ﬁndings
suggest the timeline for structural alterations in FAD due to APP
mutations may be compressed compared to LOAD, with accelerated
brain losses occurring in parallel with asymptomatic cognitive decline
on testing, and the appearance of symptoms at an early age.
Of the three known FAD genes, the presenillin-1 (PSEN1) gene on
chromosome 14 harbors the most common mutations. A study of six
CN PSEN1 mutation carriers gathered from four families found
increased cortical thickness in precuneus and parietotemporal regions
approximately 10 years before expected symptoms, whereas symp-
tomatic subjects demonstrated diffuse cortical thinning, including
areas of increase found in asymptomatic subjects [81]. Other studies
in FAD demonstrate cortical thinning in the precuneus at 4.1 years
prior to symptoms, and at 1.8 years in the posterior cingulate in
mutation carriers [82]. Thus the full trajectory of structural change in
CN persons at risk of FAD is incomplete, andmight include a very early
phase of cortical swelling or enlargement.
A large family harboring the E280A PSEN1 mutation has been
identiﬁed in Columbia, South America and characterized from the
earliest, pre-symptomatic stages through dementia, serving as a
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(449 identiﬁed mutation carriers) have not yet been reported but will
be extremely important because these subjects are likely to
participate in clinical prevention trials in the near future. Family
members who are PSEN1 carriers have a cognitive phenotype that
parallels LOAD, a decade time scale for evolution of symptoms from
earliest cognitive alterations, and certainty of dementia. In contrast,
LOAD has no model that can approach the predictive power of an
autosomal dominant mutation in patient selection for prevention
trials [82,86]. Thus, in addition to the great medical signiﬁcance of
prevention in this particular family, there are many important
implications of a successful prevention trial in this kindred for the
worldwide family of the AD-at-risk.
6. Summary and future directions
In summary, responses to the three questions posed at the
beginning of this review are:
(1) Are there structural imaging alterations in CN that precede MCI
and AD? Approximately half of normal persons harbor Braak
stage I–II neuroﬁbrillary pathology by age 55 years, approxi-
mately 20 years before nominal onset of AD at 75 years
(Fig. 1b). The neuropathologic burden increases progressively
with age thereafter, at least in many persons. The exact manner
of this progression is however unknown—whether it is linear,
stuttering in bursts, or accelerating at some time. These
unknowns become more important as we focus attention on
AD neuropathology in CN subjects. Structural alterations in CN
are observable well before dementia onset, and, when these
alterations involve gray matter, may be associated with subtle
cognitive decline in groups of clinically normal persons. Gray
matter losses during this pre-state are also associated with
ﬁbrillary amyloid burden in the brain assessed by imaging or
CSF studies, but these losses are more likely related to the
amyloid coupling to abnormal tau than to amyloid per se.
White matter diffusion changes are observed perhaps even
earlier in interhemispheric and intrahemispheric long associ-
ation tracts (cf. companion review on white matter neuroim-
aging in this issue).
(2) Is there a regional pattern of such alterations and does this pattern
provide insight into AD pathophysiology? The most consistent
ﬁnding is a decrease in medial temporal volume well before
clinically symptomatic stages (MCI or AD). However cortical
thinning has been detected in other regions in CN subjects,
particularly the temporal and parietal neocortex. Gray matter
atrophy appears in areas where AD neuroﬁbrillary pathology is
known to be heaviest, and is correlated both globally and
locally with amyloid burden. Under our framework this
association is mediated by the coupling between amyloid and
abnormal tau, the latter representing the marker for synaptic
and neuronal shrinkage and loss. For example, CN individuals
with increased global amyloid burden demonstrate strong
correlation between regional amyloid burden in the inferolat-
eral temporal lobe and hippocampal atrophy. Thus structural
imaging in gray matter, by itself, only conﬁrms gross shrinkage
of neurons and neuropil in a pattern consistent with expected
local AD neuropathology. When marked by the detection of
amyloid globally and locally, the strength of the inference
underlying AD neuropathology associated with abnormal tau
increases. Insight into how this coupling might come about is
not forthcoming from these ﬁndings alone.
White matter alterations in association ﬁbers appear to involve
large stretches of the neocortex, but a more detailed review
appearing elsewhere in this volume qualiﬁes this conclusion.
Early work suggests that white matter alterations may bereporting on altered axonal–myelin signaling interactions,
perhaps an earlier indication of underlying AD neuropathology
than gray matter atrophy.
(3) How long before clinical symptoms of MCI or AD appear do
structural alterations occur? Approximately 5–10 years for gray
matter atrophy, and perhaps longer for white matter diffusion
alterations. This estimate suggests that interventions to
prevent ADwill need to begin early indeed, before the expected
onset of even the earliest symptoms of cognitive impairment.
One understudied area of structural imaging is the analysis of
dynamic compensatory change (e.g., due to exercise or
intensive educational activity) or components of cerebral
reserve such as cortical thickness that may confer resistance
to the effects of aging, AD, and co-morbid pathologies.
Measures to enhance compensation for the presence of existing
early AD neuropathology is an underexplored area of research
in AD.
Many other questions regarding AD neuropathology in CN
remain, some of which can be addressed with structural
imaging. The answers are important for the rational consider-
ation of AD prevention. The data presented here and elsewhere
in this volume are sufﬁciently convincing that, for the purposes
of including and excluding potential participants in clinical
prevention trials, a combination of: (a) amyloid/FDDNP
imaging [12,52] or CSF [87] and (b) a structural MRI pattern
signature [67,68,71] would enhance the efﬁciency and speed of
these trials. In a long-term trial, even expense might be
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